ArticleNature medicine2024
Inhibition of lysine acetyltransferase KAT6 in ER
Erratum issuedAbstract readClinical Trial, Phase IMulticenter Study
In one paragraph
Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Dynamic regulation of H3K9 modifications in cancer: pathogenesis and targeted therapies.Biomarker research · 2026Review
- Reframing cancer therapy through tumor plasticity.Nature cancer · 2026Review
- Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer.Molecular cancer therapeutics · 2026Article
- KAT6A-inhibitor co-crystal structures: tackling a challenging crystallization target via two alternative approaches.Acta crystallographica. Section D, Structural biology · 2026Article
- Proteomic Characterization of Replication Stress and Impaired Antioxidant Defense in Tacrolimus-Induced Chronic Nephrotoxicity.International journal of molecular sciences · 2026Article
- WITHDRAWN: From CDK4/6 to CDK2 and KAT: Evolving therapeutic approaches in HR+/HER2- breast cancer.Breast (Edinburgh, Scotland) · 2026Article
- The Great Escape: the systems biology of endocrine resistance and lineage plasticity.Endocrine-related cancer · 2026Review
- Nucleic sexual hormone receptor signaling pathways in breast cancer: function regulation, crosstalk, and therapeutic implications.NPJ precision oncology · 2026Review
- The roles of the acetyltransferase domains of the chromatin regulators KAT6A and KAT6B in vivo.Development (Cambridge, England) · 2026Article
- Exploring tear biomarkers with shotgun proteomics for retinoblastoma diagnosis: a pilot study.The journal of liquid biopsy · 2026Article
- Hierarchical small molecule inhibition of MYST acetyltransferases.Nature communications · 2026Article
- Acetyl-carnitine improves hyperactivity and learning deficits inLife science alliance · 2026Article
- Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer.Current treatment options in oncology · 2026Review
- Potential Targets and Biomarkers of Radionuclide Therapy in Breast Cancer.Cancer innovation · 2026Review
- Single amino-acid differences define H2B variants and modify chromatin accessibility to induce EMT in breast cancer.Oncogene · 2026Article
- Exploring KAT6 as a therapeutic target in breast cancer: epigenetic approaches for precision medicine.NPJ breast cancer · 2025Review
- ER degradation for ERNature communications · 2025Article
- Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes.Cancer discovery · 2025Article
- Lysine Acetyltransferase 6 in Health and Disease.MedComm · 2025Review
- KAT6A acetylation regulates AMPK function and hypertrophic remodeling in the heart.Molecular metabolism · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
26 authors.
Toru MukoharaNational Cancer Center Hospital East, Kashiwa, Japan.
Yeon Hee ParkSamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.ORCID 0000-0003-4156-9212
David SommerhalderNEXT Oncology, San Antonio, TX, USA.ORCID 0000-0002-7033-9064
Kan YonemoriNational Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0002-7624-7611
Erika HamiltonSarah Cannon Research Institute, Nashville, TN, USA.ORCID 0000-0002-1911-0336
Sung-Bae KimAsan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Jee Hyun KimSeoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
Hiroji IwataNagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.
Toshinari YamashitaKanagawa Cancer Center, Yokohama, Japan.ORCID 0000-0002-6479-1660
Rachel M LaymanThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-8663-0331
Monica MitaHoag Family Cancer Institute, Newport Beach, CA, USA.
Timothy ClaySaint John of God Subiaco Hospital, Perth, Western Australia, Australia.
Yee Soo ChaeKyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Catherine OakmanWestern Health, Sunshine Hospital, St Albans, Victoria, Australia.
Fengting YanSwedish Cancer Institute, First Hill-True Family Women's Cancer Center, Seattle, WA, USA.
Gun Min KimYonsei University College of Medicine, Seoul, Republic of Korea.
Seock-Ah ImSeoul National University Hospital, Seoul National University College of Medicine, Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.
Geoffrey J LindemanPeter MacCallum Cancer Centre and Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.ORCID 0000-0001-9386-2416
Hope S RugoUniversity of California, San Francisco, CA, USA.ORCID 0000-0001-6710-4814
Marlon LiyanagePfizer, San Diego, CA, USA.ORCID 0000-0003-3801-6174
Michelle SaulPfizer, San Diego, CA, USA.
Christophe Le CorrePfizer, San Diego, CA, USA.
Athanasia SkouraPfizer, Collegeville, PA, USA.
Li LiuPfizer, San Diego, CA, USA.
Meng LiPfizer, San Francisco, CA, USA. meng.li7@pfizer.com.ORCID 0009-0002-5406-8345
Patricia M LoRussoYale School of Medicine, New Haven, CT, USA. patricia.lorusso@yale.edu.ORCID 0000-0001-7144-036X
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MNCATS NIH HHS UL1 TR001863
Abstract
Inhibition of histone lysine acetyltransferases (KATs) KAT6A and KAT6B has shown antitumor activity in estrogen receptor-positive (ER
Indexed as
Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesFulvestrantHistone AcetyltransferasesReceptors, EstrogenAdultAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMiddle AgedNeoplasm MetastasisERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFulvestrantHistone AcetyltransferasesKAT6A protein, humanReceptors, Estrogen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.